Log In
BCIQ
Print this Print this
 

OP0595, RG6080 (formerly FPI-1459)

  Manage Alerts
Collapse Summary General Information
Company Fedora Pharmaceuticals Inc.
DescriptionBeta lactamase (LACTB) inhibitor
Molecular Target Beta lactamase (LACTB)
Mechanism of ActionBeta lactamase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationBacterial infection
Indication DetailsTreat bacterial infections
Regulatory Designation
PartnerMeiji Seika Pharma Co. Ltd.;
Roche

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$750.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/13/2015

$750.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today